ArticleInternational journal of environmental research and public health2022
Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- An approach to assess the impact of measures mitigating burden associated with COVID-19 in Central Asia (Kazakhstan, Kyrgyzstan, Mongolia).Scientific reports · 2026Article
- Prevalence of healthcare-associated infections and antimicrobial use in Kazakhstan: results of the first nationwide survey in 2023.Antimicrobial resistance and infection control · 2025Article
- Systemic antiviral consumption in Kazakhstan.Scientific reports · 2025Article
- Kazakhstani Drivers and Substance Abuse During COVID-19: A Study of Patterns and Disaster Readiness.Healthcare (Basel, Switzerland) · 2025Article
- National trends in Azithromycin consumption during 2017-2023 in Kazakhstan: impact of the COVID-19 pandemic and the imperative for enhanced clinical guidelines.Scientific reports · 2025Article
- The burden of COVID-19 in primary care of Almaty, Kazakhstan, 2021-2022.Scientific reports · 2025Article
- Outpatient pediatric care during the COVID-19 pandemic, Almaty, Kazakhstan 2021-2022.Frontiers in public health · 2025Article
- PostCOVID-19 Impact on Perinatal Outcomes.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Health policy implications for cardiovascular disease, type 2 diabetes mellitus, and stroke in Central Asia: a decadal forecast of their impact on women of reproductive age.Frontiers in public health · 2024Article
- Interrupted time series analysis of the impact of the COVID-19 pandemic and compulsory social health insurance system on fertility rates: a study of live births in Kazakhstan, 2019-2023.Frontiers in public health · 2024Article
- Study of seroprevalence of SARS-CoV-2 in Kazakhstan.Epidemiology and infection · 2023Article
- High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The data on seroprevalence of anti-SARS-CoV-2 antibodies in Kazakhstani population are non-existent, but are needed for planning of public health interventions targeted to COVID-19 containment. The aim of the study was to estimate the seropositivity of SARS-CoV-2 infection in the Kazakhstani population from 2020 to 2021. We relied on the data obtained from the results from "IN VITRO" laboratories of enzyme-linked immunosorbent assays for class G immunoglobulins (IgG) and class M (IgM) to SARS-CoV-2. The association of COVID-19 seropositivity was assessed in relation to age, gender, and region of residence. Additionally, we related the monitoring of longitudinal seropositivity with COVID-19 statistics obtained from Our World in Data. The total numbers of tests were 68,732 for SARS-CoV-2 IgM and 85,346 for IgG, of which 22% and 63% were positive, respectively. The highest rates of positive anti-SARS-CoV-2 IgM results were seen during July/August 2020. The rate of IgM seropositivity was the lowest on 25 October 2020 (2%). The lowest daily rate of anti-SARS-CoV-2 IgG was 17% (13 December 2020), while the peak of IgG seropositivity was seen on 6 June 2021 (84%). A longitudinal serological study should be envisaged to facilitate understanding of the dynamics of the epidemiological situation and to forecast future scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.